myriad genetics inc (MYGN) Key Developments
Myriad Genetics Inc. Announces Prolaris Test Biopsy Results from EMPATHY-P Study at European Association of Urology Annual Meeting
Mar 20 15
Myriad Genetics Inc. announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods (D'Amico/AUA risk stratification), which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology. Specifically, EMPATHY-P demonstrated that the Prolaris test score found 22% of the European patients had less aggressive prostate cancer and 20% had more aggressive prostate cancer compared to standard clinical pathology measurements. Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy.
Myriad Genetics Seeks Acquisitions
Mar 11 15
Mark Capone, President, Chief Executive Officer & Director of Myriad Genetics Inc. (NasdaqGS:MYGN) said, "I think as we reflect on that, I would love to find other opportunities like Crescendo that are generating this level of revenue that have line of sight to being accretive in the not too distant future in a very large market that's $1.5 billion market that can be served by 40 sales people. I would love to have other acquisition opportunities in that category. Unfortunately, there are not that many quality opportunities out there in this space and that's why you haven't seen us be more acquisitive, but certainly, we would take that opportunity anytime we could get it to find an asset like that."
Myriad Genetics Launches New Blood Survey Tool
Mar 5 15
Myriad Genetics (MYGN) reported on the launch of immunoassay services based on its sensitive, single-molecule array diagnostic platform. MYGN said the platform enables the accurate measurement of protein biomarkers in blood that were previously difficult or even impossible to detect.
Myriad Genetics, Inc. Publishes myPath Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology
Mar 4 15
Myriad Genetics Inc. announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90% diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States. The published study describes the discovery, verification and clinical validation of the myPath Melanoma test, which was designed to differentiate benign moles from malignant melanoma. The myPath Melanoma test was developed using a verification cohort of 464 patient samples and was validated in a separate independent study with 437 patient samples from academic medical centers in the United States. In both the verification and validation studies, the myPath Melanoma test demonstrated a greater than 90% diagnostic accuracy, making it the most accurate molecular diagnostic test developed to date for melanoma. These clinical findings validate the performance, objectivity and reliability of the myPath Melanoma test for clinical use to improve the diagnosis of melanoma. About Myriad myPath Melanoma Testing: Myriad myPath Melanoma is a clinically validated gene expression test designed to differentiate malignant melanoma from benign nevi across all major melanoma subtypes.
Myriad Genetics Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 11:15 AM
Mar 4 15
Myriad Genetics Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 11:15 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Mark Christopher Capone, President of Myriad Genetic Laboratories.